Glycoproteomic approach for identification of heart failure-related proteins as a novel biomarker

为了开发心力衰竭的治疗策略，非常需要能够量化疾病程度的新型生物标志物。在本研究中，我们的目的是确定一种新的生物标志物，可以作为一个有价值的补充，现有的标记物，更准确的诊断和预后的心力衰竭，使用糖蛋白质组学的方法。我们首先分析了在高血压诱导的大鼠在心脏肥大和心力衰竭的左心室糖基化的配置文件，确定改变聚糖结构反映了疾病的程度。我们的数据还表明，血浆中负责糖基化特征性改变的去糖基化酶的酶活性可能是肥大的一种新生物标志物。此外，靶向左心室和血浆的糖蛋白组学分析鉴定了超过40种与心力衰竭相关的糖蛋白作为生物标志物候选物。

To develop a therapeutic strategy for heart failure, a novel biomarker which enables to quantify the degree of the disease is highly required. In the present study, we aimed to identify a novel biomarker which could serve as a valuable supplement to the existing markers for more accurate diagnosis and prognosis of heart failure, using a glycoproteomic approach.We first analyzed a glycosylation profile in the left ventricle of hypertension-induced rats during cardiac hypertrophy and heart failure, identifying altered glycan structures reflecting the degree of the disease. Our data also indicated that plasma enzymatic activity of a deglycosylation enzyme responsible for the characteristically altered glycosylation would be a novel biomarker for hypertrophy. In addition, glycoproteomic analysis targeting the left ventricle and plasma identified over 40 glycoproteins related to heart failure as biomarker candidates.